21,000 Shares in Royalty Pharma plc (NASDAQ:RPRX) Bought by Sava Infond d.o.o.

Sava Infond d.o.o. bought a new stake in Royalty Pharma plc (NASDAQ:RPRX) during the fourth quarter, HoldingsChannel reports. The firm bought 21,000 shares of the biopharmaceutical company’s stock, valued at approximately $536,000.

Other institutional investors have also recently made changes to their positions in the company. Franklin Resources Inc. lifted its position in Royalty Pharma by 5.0% during the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company’s stock worth $40,705,000 after acquiring an additional 70,130 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Royalty Pharma by 4.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company’s stock valued at $79,888,000 after buying an additional 130,025 shares in the last quarter. Pallas Capital Advisors LLC bought a new stake in Royalty Pharma during the fourth quarter worth $2,355,000. Jupiter Asset Management Ltd. acquired a new stake in Royalty Pharma in the fourth quarter valued at about $4,950,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Royalty Pharma by 303.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company’s stock valued at $13,926,000 after purchasing an additional 406,123 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Wall Street Analyst Weigh In

Separately, TD Cowen raised Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and an average target price of $41.60.

Royalty Pharma Stock Up 0.3 %

RPRX stock opened at $31.65 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $18.24 billion, a PE ratio of 21.83, a P/E/G ratio of 2.31 and a beta of 0.47. The stock’s 50 day moving average is $32.43 and its 200-day moving average is $28.82. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Sell-side analysts expect that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were issued a $0.22 dividend. The ex-dividend date was Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.78%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio (DPR) is 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.